Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.

Journal of psychopharmacology (Oxford, England) - 1 Dec 2004

Ciusani Elio, Zullino Daniele F, Eap Chin B, Brawand-Amey Marlyse, Brocard Murielle, Baumann Pierre

Abstract excerpt

The chiral antidepressant venlafaxine (VEN) is both a serotonin and a norepinephrine uptake inhibitor. CYP2D6 and CYP3A4 contribute to its metabolism, which has been shown to be stereoselective. Ten CYP2D6 genotyped and depressive (F32x and F33x, ICD-10) patients participated in an open study on the pharmacokinetic and pharmacodynamic consequences of a carbamazepine augmentation in VEN non-responders. After an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents, Second-Generation
Share to Carbamazepine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclohexanols

Share to Cytochrome P-450 CYP2D6

Share to Depressive Disorder

Share to Drug Therapy, Combination

Share to Psychiatric Status Rating Scales

Share to Venlafaxine Hydrochloride

Source

Identifiers

PMID: 15582923
DOI: 10.1177/026988110401800414

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.PMID 15582923Read ↗

Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine.Semantic proximity Read ↗

An observational study of Venlafaxine and CYP2D6 in clinical practice.Semantic proximity Read ↗

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.Semantic proximity Read ↗

Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions.Semantic proximity Read ↗

Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient.Semantic proximity Read ↗

Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A.Semantic proximity Read ↗

Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.Semantic proximity Read ↗

Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).Semantic proximity Read ↗

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.Semantic proximity Read ↗

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.Semantic proximity Read ↗

CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients.Semantic proximity Read ↗

Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.